Search stocks

Find any stock by ticker or company name

Get all premium features to the best stock analysis tool

Finranks

Company

About us

Contact us

[email protected]

Follow us

Instagram
Telegram
LinkedIn

All rights reserved.

Privacy Policy Terms of Conditions

Home
Watchlist
Markets
Screener
News
About

DOCS - Doximity, Inc. Latest News | Finranks

Home

/

DOCS

D

Doximity, Inc. (DOCS)

NYQ – Real Time Price. Currency in USD

26.45

+0.19 (0.72%)

At close: May 12, 2026, 4:00 PM EDT

26.35

-0.10 (-0.38%)

After-hours: May 12, 2026, 7:59 PM EDT

Summary
News
Chart
Financial
Dividends
Forecast
Ownership
Profile

Hims & Hers Expands Digital Healthcare Platform via New Care Offerings

Hims & Hers Expands Digital Healthcare Platform via New Care Offerings

HIMS broadens its digital health platform with Labs, menopause and testosterone care, global acquisitions and a Novo Nordisk GLP-1 tie-up.

Insights Into Doximity (DOCS) Q4: Wall Street Projections for Key Metrics

Insights Into Doximity (DOCS) Q4: Wall Street Projections for Key Metrics

Besides Wall Street's top-and-bottom-line estimates for Doximity (DOCS), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended March 2026.

Why the Market Dipped But Doximity (DOCS) Gained Today

Why the Market Dipped But Doximity (DOCS) Gained Today

The latest trading day saw Doximity (DOCS) settling at $26.03, representing a +1.32% change from its previous close.

Should You Add OPRX Stock to Your Portfolio Pre-Q1 Earnings?

Should You Add OPRX Stock to Your Portfolio Pre-Q1 Earnings?

OptimizeRx nears Q1 earnings amid declining revenue forecasts, softer trends and a cautious outlook, raising questions on near-term upside.

3 Medical Info Systems Stocks Riding the GenAI Wave in a Tough Market

3 Medical Info Systems Stocks Riding the GenAI Wave in a Tough Market

Doximity, Veeva and Omnicell ride surging GenAI adoption in healthcare, tapping digital demand despite market pressure and rising cybersecurity risks.

Doximity: Buy It As Mr. Market Is Selling It Cheap Under A Panic Attack

Doximity: Buy It As Mr. Market Is Selling It Cheap Under A Panic Attack

Doximity has seen a two-thirds stock price decline, which I attribute mainly to market overreaction and short-term uncertainty, not deteriorating fundamentals. DOCS maintains a robust business model with 90% gross margins, ~30% net margins, strong cash generation, and a dominant network among U.S. healthcare professionals. Recent growth deceleration and vague pharma client budget concerns have pressured the stock, but DOCS remains asset-light with minimal downside risk and ample liquidity.

Doximity (DOCS) Outperforms Broader Market: What You Need to Know

Doximity (DOCS) Outperforms Broader Market: What You Need to Know

In the latest trading session, Doximity (DOCS) closed at $24.66, marking a +2.71% move from the previous day.

Videos

No Data

There is no data to display

Press releases

Doximity Study Finds Physicians Rapidly Adopting AI, But Accuracy Concerns Persist

Doximity Study Finds Physicians Rapidly Adopting AI, But Accuracy Concerns Persist

SAN FRANCISCO--(BUSINESS WIRE)--Doximity, Inc. (NYSE: DOCS), the leading digital platform for U.S. medical professionals, today released a new report examining how physicians are adopting artificial intelligence (AI) in clinical practice. The findings show that AI adoption and interest are widespread: 94% of physicians reported they are currently using AI or interested in doing so. At the same time, physicians remain cautious, with 71% citing accuracy and reliability as their top concern. “AI h.

Halper Sadeh LLC Encourages Doximity Inc. Shareholders to Contact the Firm to Discuss Their Rights

Halper Sadeh LLC Encourages Doximity Inc. Shareholders to Contact the Firm to Discuss Their Rights

Shareholders should contact the firm immediately as there may be limited time to enforce your rights Shareholders should contact the firm immediately as there may be limited time to enforce your rights

Doximity Ranked #1 Best in KLAS Telehealth Video Platform for Fifth Consecutive Year

Doximity Ranked #1 Best in KLAS Telehealth Video Platform for Fifth Consecutive Year

SAN FRANCISCO--(BUSINESS WIRE)--Doximity, Inc. (NYSE: DOCS), the leading digital platform for U.S. medical professionals, announced today that Doximity Dialer has been named the #1 Telehealth Video Conferencing Platform in the 2026 Best in KLAS Report. This is the fifth consecutive year that Doximity has earned the top spot, underscoring its position as a trusted, long-term partner for physicians and health systems. In addition to securing the #1 spot, Doximity received A-level ratings in all c.

Doximity Announces Fiscal 2026 Third Quarter Financial Results

Doximity Announces Fiscal 2026 Third Quarter Financial Results

SAN FRANCISCO--(BUSINESS WIRE)--Doximity, Inc. (NYSE: DOCS), the leading digital platform for U.S. medical professionals, today announced results of its fiscal 2026 third quarter ended December 31, 2025. “We're proud to deliver another quarter of strong profits and record engagement,” said Jeff Tangney, co-founder and CEO of Doximity. “Our newsfeed had more than 1 million quarterly active prescribers, our workflow products had 720,000 (a record QoQ jump), and our nascent AI products had over 30.